DabigatranQuality Solutions

Category: Anticoagulant



USP can support your development and manufacturing activities on Dabigatran-based medicines with these existing and upcoming standards.

Official and Proposed Documentary Standards and Associated Physical Materials

MONOGRAPH 1

DABIGATRAN ETEXILATE MESYLATE COMING SOON Published in PF 48(4) 01-Jul-2022	
USP Dabigatran Etexilate Mesylate RS I New	<u>USP-1162239</u>
USP Hexyl Methanesulfonate RS I New	<u>USP-1162273</u>
USP Dabigatran Etexilate Related Compound A RS I New	<u>USP-1162240</u>
USP Dabigatran Etexilate Related Compound B RS I New	USP-1162251
USP Dabigatran Etexilate Related Compound C RS I New	<u>USP-1162262</u>

^{*} Documents in PF Online are not official and not suitable to demonstrate compliance. They may never become official.

PHARMACEUTICAL ANALYTICAL IMPURITY(IES)*

USP N-Nitroso Dabigatran Etexilate Solution PALI New USP-1A04040

O1-Dec-2023. For publications related to **Dabigatran** in *PF* online after this date, please visit the integrated *USP-NF/PF* online.

* Pharmaceutical Analytical Impurities (PAI products) are released using a process developed by USP's subject matter experts. The release process is based on internal policies, standard operating procedures, and requirements as defined by USP's Quality Management System. USP is an ISO 9001:2015 certified facility. PAI products are different from official USP Reference Standards. PAI products are not required for compendial compliance.

Disclaimer: USP Quality Solution Sheets are provided as a convenience and for informational purposes only. Labmix24 makes reasonable efforts to provide correct information but assumes no liability for the completeness, timeliness or accuracy of the information contained in each QSS. It is the responsibility of the user to verify the information. The US Pharmacopeia remains the official source of this information.

